CHICAGO TRUST Co NA Sells 428 Shares of Becton, Dickinson and Company (NYSE:BDX)

CHICAGO TRUST Co NA decreased its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 28.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,068 shares of the medical instruments supplier’s stock after selling 428 shares during the quarter. CHICAGO TRUST Co NA’s holdings in Becton, Dickinson and Company were worth $260,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of BDX. Fairfield Bush & CO. acquired a new position in shares of Becton, Dickinson and Company during the first quarter worth $114,000. Sequoia Financial Advisors LLC increased its position in shares of Becton, Dickinson and Company by 11.3% during the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock worth $778,000 after purchasing an additional 297 shares in the last quarter. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 8.8% during the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $368,000 after purchasing an additional 112 shares in the last quarter. Zions Bancorporation N.A. increased its position in shares of Becton, Dickinson and Company by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock worth $134,000 after purchasing an additional 58 shares in the last quarter. Finally, Mather Group LLC. increased its position in shares of Becton, Dickinson and Company by 26.0% during the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock worth $358,000 after purchasing an additional 278 shares in the last quarter. Institutional investors own 86.72% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $246.25 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.08 and a quick ratio of 0.64. The stock’s fifty day moving average price is $238.71 and its 200 day moving average price is $245.40. Becton, Dickinson and Company has a 1 year low of $229.85 and a 1 year high of $287.32. The company has a market cap of $71.14 billion, a price-to-earnings ratio of 58.35, a PEG ratio of 2.03 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the prior year, the firm earned $2.98 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 8th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.54%. The ex-dividend date of this dividend is Thursday, March 7th. Becton, Dickinson and Company’s payout ratio is 90.05%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.31% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent analyst reports. Morgan Stanley reduced their price target on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a research report on Monday, December 4th. Raymond James upped their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Barclays upped their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $279.17.

Check Out Our Latest Stock Analysis on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.